Concepedia

Publication | Closed Access

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

DOI

183

Citations

25

References

1995

Year

Frank H. Valone, Peter A. Kaufman, Paul M. Guyre, Lionel D. Lewis, V A Memoli, Yashwant M. Deo, R F Graziano, James L. Fisher, Larissa A. Meyer, M Mrozek-Orlowski
Journal of Clinical Oncology

Abstract

MDX-210 is immunologically active at well-tolerated doses. The MTD and OBD is 7 to 10 mg/m2.

References

YearCitations

Page 1